| Primary |
| Drug Use For Unknown Indication |
27.3% |
| Product Used For Unknown Indication |
19.7% |
| Eczema |
9.1% |
| Urticaria |
6.1% |
| Asthma |
4.5% |
| Neuropathic Pain |
4.5% |
| Seasonal Allergy |
4.5% |
| Gastrooesophageal Reflux Disease |
3.0% |
| Mineral Supplementation |
3.0% |
| Rhinitis |
3.0% |
| Alpha-1 Anti-trypsin Deficiency |
1.5% |
| Angina Pectoris |
1.5% |
| Attention Deficit/hyperactivity Disorder |
1.5% |
| Blood Pressure |
1.5% |
| Depression |
1.5% |
| Gout |
1.5% |
| Hypersensitivity |
1.5% |
| Hypertension |
1.5% |
| Nasal Congestion |
1.5% |
| Palpitations |
1.5% |
|
| Spleen Disorder |
10.3% |
| Toxic Skin Eruption |
10.3% |
| Hallucination |
6.9% |
| Metabolic Disorder |
6.9% |
| Tremor |
6.9% |
| Unevaluable Event |
6.9% |
| Vestibular Disorder |
6.9% |
| Circulatory Collapse |
3.4% |
| Convulsion |
3.4% |
| Dacryostenosis Acquired |
3.4% |
| Electrocardiogram Qt Prolonged |
3.4% |
| Face Oedema |
3.4% |
| Foetal Exposure During Pregnancy |
3.4% |
| Haemorrhage |
3.4% |
| Hepatotoxicity |
3.4% |
| Local Swelling |
3.4% |
| Myocardial Infarction |
3.4% |
| Palpitations |
3.4% |
| Paraesthesia |
3.4% |
| Pregnancy |
3.4% |
|
| Secondary |
| Epilepsy |
10.1% |
| Supraventricular Tachycardia |
9.3% |
| Rash |
8.3% |
| Dermatitis |
8.0% |
| Chronic Obstructive Pulmonary Disease |
7.8% |
| Product Used For Unknown Indication |
7.8% |
| Tachycardia Paroxysmal |
6.2% |
| Drug Use For Unknown Indication |
5.7% |
| Pruritus |
4.7% |
| Prophylaxis |
4.1% |
| Pain |
3.4% |
| Thrombosis Prophylaxis |
3.4% |
| Grand Mal Convulsion |
3.1% |
| Rheumatoid Arthritis |
3.1% |
| Sleep Disorder |
2.8% |
| Conjunctivitis |
2.6% |
| Essential Hypertension |
2.6% |
| Nausea |
2.6% |
| Vomiting |
2.6% |
| Asthma |
2.1% |
|
| Toxic Epidermal Necrolysis |
23.9% |
| Abortion Spontaneous |
10.9% |
| Paraesthesia |
8.7% |
| Rash |
6.5% |
| Rash Maculo-papular |
6.5% |
| Exposure During Pregnancy |
4.3% |
| Hallucination |
4.3% |
| Rash Macular |
4.3% |
| Spleen Disorder |
4.3% |
| Toxic Skin Eruption |
4.3% |
| Arthralgia |
2.2% |
| Cytolytic Hepatitis |
2.2% |
| Drug Exposure During Pregnancy |
2.2% |
| Drug Interaction |
2.2% |
| Eosinophilia |
2.2% |
| Hepatitis |
2.2% |
| Intraocular Pressure Increased |
2.2% |
| Myocardial Infarction |
2.2% |
| Pruritus |
2.2% |
| Suicide Attempt |
2.2% |
|
| Concomitant |
| Drug Use For Unknown Indication |
28.6% |
| Product Used For Unknown Indication |
11.9% |
| Prophylaxis |
6.7% |
| Depression |
6.5% |
| Hypertension |
5.8% |
| Asthma |
4.7% |
| Urticaria |
3.9% |
| Premedication |
3.2% |
| Rheumatoid Arthritis |
3.2% |
| Hypersensitivity |
3.0% |
| Myocardial Ischaemia |
2.8% |
| Seasonal Allergy |
2.8% |
| Arthralgia |
2.6% |
| Insomnia |
2.3% |
| Abdominal Pain Upper |
2.1% |
| Colorectal Cancer |
2.1% |
| Hepatitis C |
2.1% |
| Anxiety |
1.9% |
| Eczema |
1.9% |
| Mucopolysaccharidosis I |
1.9% |
|
| Urticaria |
15.8% |
| Somnolence |
6.6% |
| Urinary Tract Infection |
6.6% |
| Toxic Skin Eruption |
5.3% |
| Vision Blurred |
5.3% |
| Vomiting |
5.3% |
| Weight Decreased |
5.3% |
| Wheezing |
5.3% |
| Withdrawal Syndrome |
5.3% |
| Extrasystoles |
3.9% |
| General Physical Health Deterioration |
3.9% |
| Interstitial Lung Disease |
3.9% |
| Paraesthesia |
3.9% |
| Rash |
3.9% |
| Sudden Death |
3.9% |
| Tachycardia |
3.9% |
| Ulnar Nerve Palsy |
3.9% |
| Abortion Spontaneous |
2.6% |
| Anaphylactic Reaction |
2.6% |
| Arteriovenous Fistula Site Complication |
2.6% |
|
| Interacting |
| Mineral Supplementation |
33.3% |
| Prophylaxis |
16.7% |
| Pruritus |
16.7% |
| Blood Pressure |
8.3% |
| Blood Pressure Management |
8.3% |
| Pruritus Generalised |
8.3% |
| Alpha-1 Anti-trypsin Deficiency |
4.2% |
| Attention Deficit/hyperactivity Disorder |
4.2% |
|
| Paraesthesia |
80.0% |
| Trismus |
20.0% |
|
